Genetron rises as FDA grants liver cancer test breakthrough device status

Genetron Holdings

30/09/2020 14:20

** U.S.-listed shares of Chinese medtech firm Genetron
Holdings  GTH.O  gains 8.2% to $10.50 in premarket trade 
    ** U.S. FDA grants breakthrough device designation to co's
blood-based next-generation sequencing test,
HCCscreen urn:newsml:reuters.com:*:nGNX6XSkVl
    ** The test is for early detection of liver cancer in people
at high-risk due to chronic hepatitis B virus (HBV) infection
and/or liver cirrhosis
    ** Company expects to announce the full data set from all
2,000 trial patients in the first half of 2021
    ** Stock debuted on the Nasdaq on June 19

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))